Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar lavage in COPD patients and in lung tissue from advanced emphysema

International Journal of COPD

Volumn 2, Issue 4, 2007, Pages 643-650

  Brandén, Eva ^a,c   Gnarpe, Judy ^b   Hillerdal, Gunnar ^a   Orre, Lotta ^c   Sköld, C Magnus ^a   Löfdahl, Magnus ^a   Koyi, Hirsh ^a   Tornling, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bronchoalveolar lavage; Chlamydia pneumoniae; COPD; Cytospin; Lung tissue

Indexed keywords

BACTERIUM ANTIBODY; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IPRATROPIUM BROMIDE; MONOCLONAL ANTIBODY; SALBUTAMOL; TERBUTALINE;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIUM DETECTION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LUNG EMPHYSEMA; LUNG LAVAGE; LUNG PARENCHYMA; LUNG RESECTION; MALE; PATHOGENESIS; SMOKING;

BRONCHOALVEOLAR LAVAGE; CHLAMYDOPHILA PNEUMONIAE; CYTODIAGNOSIS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESPIRATORY FUNCTION TESTS; SWEDEN;

EID: 38049171309     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Branden E, Koyi H, Gnarpe J, et al. 2005. Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. Respir Med, 99:20-6.
2. Campbell LA, Kuo CC, Grayston JT. 1998. Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis, 4:571-9.
3. Dowell SF, Peeling RW, Boman J, et al. 2001. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis, 33:492-503.
4. GnarpeJ, NaasJ, Lundback A. 2000. Comparison of a new commercial EIA kit and the microimmunofluorescence technique for the determination of IgG and IgA antibodies to Chlamydia pneumoniae. APMIS, 108:819-24.
5. Gnarpe J, Sparr A, Naas J, et al. 2000. Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration. APMIS, 108:357-62.
6. Grayston JT. 1989. Chlamydia pneumoniae, strain TWAR. Chest, 95:664-9.
7. Haslam P, Baughman R, eds. 1999. Report of European Respiratory Society (ERS) Task Force: guidelines for measurement of acellular components and recommendations for standardization of bronchoalveolar lavage (BAL). Eur Respir Rev, 9:25-157.
8. Jackson LA, Wang SP, Nazar-Stewart V, et al. 2000. Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer. Cancer Epidemiol Biomarkers Prev, 9:1263-6.
9. Kocazeybek B. 2003. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. J Med Microbiol, 52:721-6.
10. Koyi H, Branden E, Gnarpe J, et al. 2001. An association between chronic infection with Chlamydia pneumoniae and lung cancer A prospective 2-year study. APMIS, 109:572-80.
11. Kuo C, Campbell LA. 2000. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis, 181 (Suppl 3):S432-6.
12. Kurashima K, Kanauchi T, Takayanagi N, et al. 2005. Serum IgG and IgA antibodies to Chlamydia pneumoniae and severity of emphysema. Respirology, 10:572-8.
13. Laurila AL, Anttila T, Laara E, et al. 1997. Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer. Int J Cancer, 74:31-4.
14. Linden M, Rasmussen JB, Piitulainen E, et al. 1993. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis, 148:1226-32.
15. Lofdahl JM, Cederlund K, Nathell L, et al. 2005. Bronchoalveolar lavage in COPD: fluid recovery correlates with the degree of emphysema. Eur Respir J, 25:275-81.
16. Lopez AD, Murray CC. 1998. The global burden of disease 1990-2020. Nat Med, 4:1241-3.
17. Michaud CM, Murray CJ, Bloom BR. 2001. Burden of disease - implications for future research. JAMA, 285:535-9.
18. Muhlestein JB, Hammond EH, Carlquist JF, et al. 1996. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol, 27:1555-61.
19. Quanjer PH. 1983. Standardized lung function testing. Report working party standardization lung function tests. European Community for Coal and Steel. Bull Europ Physiopath Respir, 19:1-95.
20. Quanjer PH, Tammeling GJ, Cotes JE, et al. 1993. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J, 6(Suppl 16):5-40.
21. Rupp J, Droeman D, Goldmann T, et al. 2004. Alveolar epithelial cells type II are major target cells for C. pneumoniae in chronic but not in acute respiratory infection. FEMS Immunol Med Microbiol, 41:197-203.
22. Saikku P, Leinonen M, Mattila KJ, et al. 1988. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet, 2:983-6.
23. Saikku P, Leinonen M, Tenkanen L, et al. 1992. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med, 116:273-8.
24. Smieja M, Leigh R, Petrich A, et al. 2002. Smoking, season and detection of chlamydia pneumoniae DNA in clinically stable COPD patients. BMC Infectious Dis, 2:12.
25. Soler N, Ewig S, Torres A, et al. 1999. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J, 14:1015-22.
26. Theegarten D, Anhem 0, Hotzel H, et al. 2004. A comparative ultrastructural and molecular biological study on Chlamydia psittaci infection and alpha-I antitrypsin deficiency and non alpha-I antitrypsin deficiency emphysema versus lung tissue of patients with hamartochondroma. BMC Infectious Dis, 4:38.
27. von Hertzen L, Alakarppa H, Koskinen R, et al. 1997. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect, 118:155-64.
28. von Hertzen L, lsoaho R, Leinonen M, et al. 1996. Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int J Epidemiol, 25:658-64.
29. Webley WC, Salva PS, Andrzejewski C, et al. 2005. The bronchial lavage of pediatric patients with asthma contains infectious Chlamydia. Am J Respir Crit Care Med, 171:1083-8.
30. Wu L, Skinner SJ, Lambie N, et al. 2000. Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 162:1148-51.